The already harried drug maker Ranbaxy Laboratories is set for more troubles as reports from Brussels says that the European Union anti-trust regulators may fine the domestic pharma company for allegedly blocking of entry of cheaper generic medicines in the market.
It can be noted that Ranbaxy had to shell out a whopping $500 million to the US government to settle a case that involved the company fudging data for years in the world's largest pharma market last month.
This has had its current Japanese owners Daichi group threatening arbitrations against the ex-Ranbaxy owners – the brothers Malvinder and Shivinder Singh.Reports from Europe said Ranbaxy is among the nine companies that are to be fined for the allegedly blocking the entry of the generic medicines in the EU.
